Parameter
| Biomarker | Anti-saccharomyces cerevisiae Anti | Full name | Anti-saccharomyces cerevisiae Anti | Molecular Type | Immunoglobulin (IgG/IgA) |
|---|---|---|---|---|---|
| Molecular Formula | Human ASCA (IgG/IgA): C₆₃₂H₉８₄N₁₆₄O₁₉６S₈ (IgG), C₆₂０H₉６２N₁６０O₁９２S₈ (IgA) | Molecular Weight | ~150 kDa (IgG), ~160 kDa (IgA) | Core Functional Dimensions | Identification OF DISEASE subtypes |
| Disease | Inflammatory Bowel Disease (IBD) | Disease Subtypes | / | ||
| Organ | Intestine | Test Sample / Technology Platform | Anti-saccharomyces cerevisiae Antibodies (ASCA) | ||
| Pathobiological Mechanisms | (1) 50-60% of CD patients (< 15% of UC patients) show positive autoantibodies against mannan in the cell wall of S. cerevisiae, which are associated with CD penetrating phenotypes such as ileal involvement and fistula formation; Activation of the complement system (classical pathway) aggravates intestinal mucosal injury. The endoscopic inflammation score (CDEIS) of ASCA positive CD patients is significantly higher than that of negative patients; The specificity of ASCA+/ P-ANCA-pattern in differentiating CD from UC was 92%, and the accuracy rate was 85% | ||||
| Clinical Availability Status | Clinical routine auxiliary application | ||||
| Notes and Dynamics | 1. Combined anti-OmpC and anti-Cbir1 antibodies could increase the diagnostic sensitivity of CD from 67% to 83% (Am J Gastroenterol Study, 2024); (2) When ASCA titer > 100U/mL, the endoscopic recurrence rate of CD patients one year after surgery increases by 40%, and it is recommended to strengthen follow-up monitoring | ||||